Skip to main content
SpringerLink
Log in

Polypharmacy increases risk of AEs in patients with AF initiating VKAs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Martinez-Montesinos L, et al. Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity? Biomedicine and Pharmacotherapy : 12 Dec 2022. Available from: URL: https://doi.org/10.1016/j.biopha.2022.114064

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polypharmacy increases risk of AEs in patients with AF initiating VKAs. Reactions Weekly 1937, 12 (2022). https://doi.org/10.1007/s40278-022-29692-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-29692-0

Search

Navigation